CYTK - Cytokinetics Incorporated (CYTK) Q1 2024 Earnings Call Transcript

2024-05-09 00:06:04 ET

Cytokinetics, Incorporated (CYTK)

Q1 2024 Earnings Conference Call

May 08, 2024, 04:30 PM ET

Company Participants

Diane Weiser - SVP of Corporate Communication and IR

Robert Blum - President and CEO

Fady Malik - EVP of R&D

Stuart Kupfer - SVP and Chief Medical Officer

Andrew Callos - EVP and Chief Commercial Officer

Robert Wong - VP and Chief Accounting Officer

Conference Call Participants

Paul Choi - Goldman Sachs

Srikripa Devarakonda - Truist Securities

Tessa Romero - JPMorgan

Roanna Ruiz - Leerink

Salim Syed - Mizuho

Jeff Hung - Morgan Stanley

Mayank Mamtani - B. Riley Securities

Jason Butler - Citizens JMP

Cameron Bozdog - BofA

Carter Gould - Barclays

Yasmeen Rahimi - Piper Sandler

Serge Belanger - Needham

Ashwani Verma - UBS

Sean McCutcheon - Raymond James

Presentation

Operator

Good afternoon. And welcome ladies and gentlemen to Cytokinetics First Quarter 2024 Conference Call. [Operator Instructions]

I will now turn the call over to Diane Weiser, Cytokinetics, Senior Vice President of Corporate Affairs. Please go ahead.

Diane Weiser

Good afternoon. And thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Fady Malik, EVP of R&D, will provide updates related to aficamten focused to SEQUOIA-HCM and FOREST-HCM and recent interactions with FDA. Stuart Kupfer, SVP and Chief Medical Officer, will provide additional updates regarding the ongoing clinical trials of aficamten, MAPLE-HCM and ACACIA-HCM and will also discuss progression of CK-586 and our emerging pipeline. Andrew Callos, EVP and Chief Commercial Officer, will speak about commercial readiness activities for aficamten. Sung Lee, our new EVP and Chief Financial Officer is with us today, but just listening alongside us as this is his first day at Cytokinetics. Robert Wong, VP and Chief Accounting Officer will provide a financial overview of the past quarter. And finally, Robert Blum will review our corporate development strategies before closing the call by reviewing expected key milestones for the year.

Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements. Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements contained in our SEC filings, including our current report regarding our first quarter 2024 financial results filed on Form 8-K that was furnished to the SEC today. We undertake no obligation to update any forward-looking statements after this call.

And now I will turn the call over to Robert.

Robert Blum

Thank you, Diane, and thanks for joining us on the call today.

In the first quarter, we made substantial progress executing on our muscle biology focused portfolio, anchored by the broad development program of aficamten. On the heels of positive top line results from SEQUOIA-HCM, our pivotal Phase 3 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy, we are running at full throttle in preparation for an ambitious set of presentations and publications scheduled to occur over the course of the year.

In addition, we are laser-focused on regulatory submissions in the second half of the year, continued conduct of the ongoing clinical trials program, accelerating our commercial readiness activities and further expanding our pipeline.

While top line results of SEQUOIA-HCM announced last December, included a comprehensive high-level view of the safety and efficacy of aficamten, a priority of ours is to present more fully the results from SEQUOIA-HCM at a major medical meeting. Recently, we announced that, that Forum will be the European Society of Cardiology Heart Failure 2024 Congress in Lisbon next week, Monday, May 13, where we will have three late-breaking clinical trial presentations related to SEQUOIA-HCM....

For further details see: